3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Oligometastatic Prostate Carcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Cancer Pain
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
olaparib
1
Pluvicto
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Genital Neoplasms, Male
×
Abiraterone Acetate
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled